Lipocine Inc Share Price Today: Live Updates & Key Insights

Lipocine Inc share price today is $7.1, up -2.19%. The stock opened at $7.31 against the previous close of $7.31, with an intraday high of $7.31 and low of $6.91.

Lipocine Inc Share Price Chart

Lipocine Inc

us-stock
To Invest in {{usstockname}}
us-stock

Lipocine Inc Share Price Performance

$7.1 -0.0219(-2.19%) LPCN at 23 Mar 2026 02:00 PM Biotechnology
Lowest Today 6.91
Highest Today 7.31
Today’s Open 7.31
Prev. Close 7.31
52 Week High 12.37
52 Week Low 2.52
Day’s Range: Low 6.91 High 7.31
52-Week Range: Low 2.52 High 12.37
1 day return -
1 Week return -4.55
1 month return -28.21
3 month return +63.98
6 month return +141.95
1 year return +92.22
3 year return +23.95
5 year return -75.77
10 year return -

Lipocine Inc Institutional Holdings

Squadron Capital Management LLC 8.61

Vanguard Group Inc 3.60

Vanguard Total Stock Mkt Idx Inv 2.57

BlackRock Inc 1.45

Persistent Asset Partners Limited 1.15

Vanguard Institutional Extnd Mkt Idx Tr 1.04

Geode Capital Management, LLC 1.01

BOOTHBAY FUND MANAGEMENT, LLC 0.89

Renaissance Technologies Corp 0.61

Fidelity Extended Market Index 0.52

Susquehanna International Group, LLP 0.40

State Street Corp 0.30

Blackrock Extended Mkt Fund CF 0.27

Extended Equity Market Fund K 0.23

Northern Trust Corp 0.21

Dimensional Fund Advisors, Inc. 0.20

Jane Street Group LLC 0.17

Fidelity Total Market Index 0.16

Spartan Extended Market Index Pool F 0.16

Barclays PLC 0.15

Fidelity Series Total Market Index 0.14

Northern Trust Extended Eq Market Idx 0.14

NT Ext Equity Mkt Idx Fd - L 0.14

Blackrock US Eq Mkt Fund CF 0.13

U.S. Equity Market Fund F 0.11

NT Ext Equity Mkt Idx Fd - NL 0.09

T. Rowe Price U.S. Equities Tr 0.09

Fidelity Nasdaq Composite Index 0.08

Spartan Total Market Index Pool G 0.08

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.07

DFA US Vector Equity Class F 0.06

Vanguard Instl Ttl Stck Mkt Idx Tr 0.06

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.05

UBS Group AG 0.03

Morgan Stanley - Brokerage Accounts 0.01

CALDWELL SUTTER CAPITAL INC 0.01

Group One Trading, LP 0.00

Advisor Group Holdings, Inc. 0.00

FMR Inc 0.00

SBI Securities Co Ltd 0.00

Lipocine Inc Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Lipocine Inc Fundamentals

Market Cap 52.19 M

PB Ratio 3.6858

PE Ratio 0.0

Enterprise Value 38.43 M

Total Assets 17.01 M

Volume 79353

Lipocine Inc Company Financials

Annual Revenue FY23:-3067006 -3.1M, FY22:500000 0.5M, FY21:16140838 16.1M, FY20:0 0.0M, FY19:164990 0.2M

Annual Profit FY23:null 0.0M, FY22:-8056888 -8.1M, FY21:8475279 8.5M, FY20:-9748469 -9.7M, FY19:-7303220 -7.3M

Annual Net worth FY23:-16299742 -16.3M, FY22:-10758636 -10.8M, FY21:-634399 -0.6M, FY20:-20964819 -21.0M, FY19:-13007344 -13.0M

Quarterly Revenue Q3/2025:114574 0.1M, Q2/2025:622849 0.6M, Q1/2025:93864 0.1M, Q3/2024:0 0.0M, Q2/2024:89565 0.1M

Quarterly Profit Q3/2025:114574 0.1M, Q2/2025:-1513920 -1.5M, Q1/2025:93864 0.1M, Q3/2024:null 0.0M, Q2/2024:-1785156 -1.8M

Quarterly Net worth Q3/2025:-3186832 -3.2M, Q2/2025:-2205716 -2.2M, Q1/2025:-1864873 -1.9M, Q3/2024:-2218818 -2.2M, Q2/2024:-3068634 -3.1M

About Lipocine Inc & investment objective

Company Information Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

Organisation Biotechnology

Employees 14

Industry Biotechnology

CEO Dr. Mahesh V. Patel Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Lipocine Inc FAQs

What is the share price of Lipocine Inc today?

The current share price of Lipocine Inc is $7.1.

Can I buy Lipocine Inc shares in India?

Yes, Indian investors can buy Lipocine Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Lipocine Inc shares in India?

You can easily invest in Lipocine Inc shares from India by:

Can I buy fractional shares of Lipocine Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Lipocine Inc?

Lipocine Inc has a market cap of $52.19 M.

In which sector does Lipocine Inc belong?

Lipocine Inc operates in the Biotechnology sector.

What documents are required to invest in Lipocine Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Lipocine Inc?

The PE ratio of Lipocine Inc is N/A and the PB ratio is 3.69.